Delivering Small Interfering RNA for Novel Therapeutics

The gene silencing capability of RNA interference (RNAi) is being used to study individual gene's biological function and role in biochemical pathways. However, the efficacy of RNAi depends upon efficient delivery of the intermediates of RNAi, small interfering RNA (siRNA) oligonucleotides. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Patrick Y., Woodle, Martin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2008
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122746/
https://www.ncbi.nlm.nih.gov/pubmed/18369963
http://dx.doi.org/10.1007/978-1-59745-210-6_3
_version_ 1783515484717580288
author Lu, Patrick Y.
Woodle, Martin C.
author_facet Lu, Patrick Y.
Woodle, Martin C.
author_sort Lu, Patrick Y.
collection PubMed
description The gene silencing capability of RNA interference (RNAi) is being used to study individual gene's biological function and role in biochemical pathways. However, the efficacy of RNAi depends upon efficient delivery of the intermediates of RNAi, small interfering RNA (siRNA) oligonucleotides. The delivery challenge is even greater when the aim is to inhibit the expression of target genes in disease tissues. In vivo delivery of siRNA is complicated and challenging, and recent works on various animal disease models and early successes in human clinical trials are enlightening the tremendous potential of RNAi therapeutics. In this chapter, the latest developments of in vivo delivery of siRNA and the critical issues related to this effort are addressed.
format Online
Article
Text
id pubmed-7122746
institution National Center for Biotechnology Information
language English
publishDate 2008
record_format MEDLINE/PubMed
spelling pubmed-71227462020-04-06 Delivering Small Interfering RNA for Novel Therapeutics Lu, Patrick Y. Woodle, Martin C. Drug Delivery Systems Article The gene silencing capability of RNA interference (RNAi) is being used to study individual gene's biological function and role in biochemical pathways. However, the efficacy of RNAi depends upon efficient delivery of the intermediates of RNAi, small interfering RNA (siRNA) oligonucleotides. The delivery challenge is even greater when the aim is to inhibit the expression of target genes in disease tissues. In vivo delivery of siRNA is complicated and challenging, and recent works on various animal disease models and early successes in human clinical trials are enlightening the tremendous potential of RNAi therapeutics. In this chapter, the latest developments of in vivo delivery of siRNA and the critical issues related to this effort are addressed. 2008 /pmc/articles/PMC7122746/ /pubmed/18369963 http://dx.doi.org/10.1007/978-1-59745-210-6_3 Text en © Humana Press, a part of Springer Science + Business Media, LLC 2008 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Lu, Patrick Y.
Woodle, Martin C.
Delivering Small Interfering RNA for Novel Therapeutics
title Delivering Small Interfering RNA for Novel Therapeutics
title_full Delivering Small Interfering RNA for Novel Therapeutics
title_fullStr Delivering Small Interfering RNA for Novel Therapeutics
title_full_unstemmed Delivering Small Interfering RNA for Novel Therapeutics
title_short Delivering Small Interfering RNA for Novel Therapeutics
title_sort delivering small interfering rna for novel therapeutics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122746/
https://www.ncbi.nlm.nih.gov/pubmed/18369963
http://dx.doi.org/10.1007/978-1-59745-210-6_3
work_keys_str_mv AT lupatricky deliveringsmallinterferingrnafornoveltherapeutics
AT woodlemartinc deliveringsmallinterferingrnafornoveltherapeutics

Ejemplares similares